Applied Radiation Oncology

Applied Radiation Oncology

Online Audio and Video Media

Scotch Plains, New Jersey 77 followers

Our mission is to educate and engage with radiation oncology professionals around the world.

About us

Applied Radiation Oncology is published quarterly (March, June, September, December) and aims to provide a practical overview of the issues facing radiation oncologists and the clinical specialists aiding them in the management and treatment of cancer patients. Through clinical review articles, research articles and case studies authored by physicians in a double-blind peer review manner, we hope to provide you with information that you can use in your clinical practice. Applied Radiation Oncology is published by Anderson Publishing, Ltd., 180 Glenside Ave., Scotch Plains, NJ 07076. Anderson Publishing also publishes Applied Radiology.

Industry
Online Audio and Video Media
Company size
2-10 employees
Headquarters
Scotch Plains, New Jersey
Type
Educational
Founded
1992
Specialties
Radiation Oncology

Locations

Employees at Applied Radiation Oncology

Updates

  • GE HealthCare Announce AI-Based Cloud-First Application to Bring Together Disparate Oncology Data 🔗 https://bit.ly/3YGyr3a “Tampa General Hospital is looking forward to evaluating CareIntellect for Oncology to provide our care teams with information to move from analysis to action—including making use of the proactive pathways to inform care progression and clinical trial eligibility information,” said Dr. Peter Chang, Senior Vice President, Chief Transformation Officer at Tampa General Hospital. “We were impressed by how quickly GE HealthCare was able to design the application to include breast cancer in a matter of weeks. We look forward to putting this in the hands of our care teams and using the AI-enabled functionality to help clinicians spend time where it matters most—delivering outstanding patient care.”

    • No alternative text description for this image
  • Planning Target Volume Margin Assessment of Retroperitoneal Tumors Using Robotic SBRT With Spine Tracking 🔗 https://bit.ly/3PPdiPt When treating retroperitoneal tumors with robotic SBRT, a minimum isometric margin expansion of 5 mm when creating the PTV is recommended if spine tracking is used for intrafraction motion assessment. Target volumes adjacent to the vertebral column may have PTV margins decreased to 4 mm without compromise in target coverage.

    • No alternative text description for this image
  • 🔗 https://bit.ly/49g7yFG “It is an explainable AI tool, which means that it shows the reasoning behind its decision-making. This makes it easier not only for doctors to make decisions, but also to provide data-backed explanations to their patients,” said Dr Rattay, who is a consultant breast surgeon and Associate Professor at the Leicester Cancer Research Centre, University of Leicester (UK).

    • No alternative text description for this image
  • Positive Findings Reported for SECuRE Copper-67 Clinical Trial 🔗 https://bit.ly/4dT7PR2 Clarity Pharmaceuticals shared several updates on the 67Cu-SAR-bisPSMA program. Cohort 4 is anticipated to be the final cohort in the dose escalation phase of the SECuRE study (pending final safety assessment by the Safety Review Committee [SRC]), with participants receiving a minimum of 2 and a maximum of 4 doses of 67Cu-SAR-bisPSMA at 12GBq.

    • No alternative text description for this image
  • 🔗 https://bit.ly/43wYydL “We know that in young patients, there is a higher chance of the breast cancer returning in the same place following breast-conserving treatment. In this trial we were aiming to lower that risk by giving patients a high radiotherapy boost directed at the site of the tumour. We were also comparing a higher and lower dose to see which one worked best for young patients in terms of local control and cosmetic outcome.”

    • No alternative text description for this image
  • Dual Immunotherapy with Chemotherapy Benefits Specific Subgroup of Lung Cancer Patients 🔗 https://bit.ly/48d9BeB "These findings support that NSCLC patients with STK11 or KEAP1 mutations are relatively resistant to standard combinations of PD-(L)1 inhibitors and chemotherapy, but can benefit markedly when a CTLA-4 inhibitor is added to their treatment regimen," said co-lead author John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology. "We are optimistic that these results will prompt clinicians to consider this novel therapeutic approach as a preferred treatment option."

    • No alternative text description for this image

Similar pages

Browse jobs